tyramine has been researched along with Parkinson Disease in 51 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Rasagiline mesylate is a novel irreversible selective monoamine oxidase type B inhibitor for Parkinson disease that may have a low risk of interaction with dietary tyramine because of its selectivity." | 9.13 | Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. ( Salzman, P; Schwid, SR; White, WB, 2008) |
| "Rasagiline is an irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of the signs and symptoms of idiopathic Parkinson disease as initial monotherapy and as adjunct therapy to levodopa." | 8.88 | The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? ( Chen, JJ; Wilkinson, JR, 2012) |
| " Rasagiline mesylate is a novel irreversible selective monoamine oxidase type B inhibitor for Parkinson disease that may have a low risk of interaction with dietary tyramine because of its selectivity." | 5.13 | Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. ( Salzman, P; Schwid, SR; White, WB, 2008) |
| "Rasagiline is an irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of the signs and symptoms of idiopathic Parkinson disease as initial monotherapy and as adjunct therapy to levodopa." | 4.88 | The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? ( Chen, JJ; Wilkinson, JR, 2012) |
| " Patients with PD+NOH had normal bradycardia responses to edrophonium and normal epinephrine responses to glucagon." | 3.74 | Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension. ( Goldstein, DS; Holmes, C; Imrich, R; Pechnik, S; Sharabi, Y, 2008) |
| "This randomized, double-blind, placebo-, comparator (selegiline 10 mg/day)-, and positive (phenelzine 30 mg/day)-controlled study investigated the pressor response to oral tyramine under fasting conditions after the administration of safinamide at therapeutic (100 mg/day) and supratherapeutic (350 mg/day) dosing regimens in healthy volunteers for the purpose of assessing the need for dietary restrictions." | 2.77 | The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. ( Astruc, B; Johne, A; Kovar, A; Krösser, S; Kupas, K; Marquet, A; Patat, A, 2012) |
| "Early diagnosis of Parkinson's disease (PD) remains a challenge to date." | 1.51 | Different Circulating Trace Amine Profiles in De Novo and Treated Parkinson's Disease Patients. ( Baraldi, E; D'Andrea, G; Giordano, G; Gucciardi, A; Leon, A; Pizzolato, G; Stocchero, M, 2019) |
| "Diseases characterized by neurogenic orthostatic hypotension (NOH), such as Parkinson disease (PD) and pure autonomic failure (PAF), are associated with cardiac sympathetic denervation, as reflected by low myocardial concentrations of 6-[(18)F]fluorodopamine-derived radioactivity." | 1.35 | Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension. ( Bentho, O; Eldadah, BA; Goldstein, DS; Grossman, E; Holmes, C; Imrich, R; Pechnik, S; Sharabi, Y, 2009) |
| "There is denervation supersensitivity in PD patients that is, however, insufficient to shift the dose-response curve to the left." | 1.35 | Systemic postganglionic adrenergic studies do not distinguish Parkinson's disease from multiple system atrophy. ( Lipp, A; Low, PA; Sandroni, P, 2009) |
| "Parkinson's disease is characterized by the loss of dopamine (DA) neurons, which leads to overactivity of the surviving DA neurons and an increase in neurotransmitter release and turnover." | 1.31 | Oxidative stress, mitochondrial respiration, and Parkinson's disease. ( Cohen, G, 2000) |
| "Although the selective monoamine oxidase (MAO) B inhibitor, (-)deprenyl, has been shown to be free from the "cheese effect" in man after tyramine challenge, the reason for this is far from clear: it may well be independent of the selective inhibitory action of the drug, for during chronic administration there is some evidence to suggest that both A and B forms of the enzyme are equally inhibited." | 1.26 | Absence of "cheese effect" during deprenyl therapy: some recent studies. ( Ashford, A; Glover, V; Sandler, M; Stern, GM, 1978) |
| "Levodopa induced an increase of about 400 fold in urinary DA; DOPAC was increased about 300 fold, 3-MT only about 70 fold, but HVA about 300 fold." | 1.25 | Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations. ( Rinne, UK; Siirtola, T; Sonninen, V, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (47.06) | 18.7374 |
| 1990's | 7 (13.73) | 18.2507 |
| 2000's | 11 (21.57) | 29.6817 |
| 2010's | 6 (11.76) | 24.3611 |
| 2020's | 3 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Distinto, S | 1 |
| Yáñez, M | 1 |
| Alcaro, S | 1 |
| Cardia, MC | 1 |
| Gaspari, M | 1 |
| Sanna, ML | 1 |
| Meleddu, R | 1 |
| Ortuso, F | 1 |
| Kirchmair, J | 1 |
| Markt, P | 1 |
| Bolasco, A | 1 |
| Wolber, G | 1 |
| Secci, D | 1 |
| Maccioni, E | 1 |
| Albillos, SM | 1 |
| Montero, O | 1 |
| Calvo, S | 1 |
| Solano-Vila, B | 1 |
| Trejo, JM | 1 |
| Cubo, E | 1 |
| Su, Y | 1 |
| Liu, Y | 1 |
| He, D | 1 |
| Hu, G | 1 |
| Wang, H | 1 |
| Ye, B | 1 |
| He, Y | 1 |
| Gao, X | 1 |
| Liu, D | 1 |
| Meiring, L | 1 |
| Petzer, JP | 1 |
| Legoabe, LJ | 1 |
| Petzer, A | 1 |
| D'Andrea, G | 1 |
| Pizzolato, G | 1 |
| Gucciardi, A | 1 |
| Stocchero, M | 1 |
| Giordano, G | 1 |
| Baraldi, E | 1 |
| Leon, A | 1 |
| Imrich, R | 3 |
| Eldadah, BA | 2 |
| Bentho, O | 2 |
| Pechnik, S | 3 |
| Sharabi, Y | 3 |
| Holmes, C | 3 |
| Grossman, E | 1 |
| Goldstein, DS | 3 |
| White, WB | 2 |
| Salzman, P | 1 |
| Schwid, SR | 2 |
| Isaacson, SH | 1 |
| Lipp, A | 1 |
| Sandroni, P | 1 |
| Low, PA | 1 |
| Goren, T | 1 |
| Adar, L | 1 |
| Sasson, N | 1 |
| Weiss, YM | 1 |
| Chen, JJ | 1 |
| Wilkinson, JR | 1 |
| Marquet, A | 1 |
| Kupas, K | 1 |
| Johne, A | 1 |
| Astruc, B | 1 |
| Patat, A | 1 |
| Krösser, S | 1 |
| Kovar, A | 1 |
| Clarke, A | 1 |
| Johnson, ES | 1 |
| Mallard, N | 1 |
| Corn, TH | 1 |
| Johnston, A | 1 |
| Boyce, M | 1 |
| Warrington, S | 1 |
| MacMahon, DG | 1 |
| Youdim, MB | 4 |
| Riederer, PF | 1 |
| Gluck, MR | 1 |
| Zeevalk, GD | 1 |
| deMarcaida, JA | 1 |
| Blindauer, K | 1 |
| Fahn, S | 2 |
| Kieburtz, K | 1 |
| Stern, M | 1 |
| Shoulson, I | 1 |
| Drozak, J | 1 |
| Kozłowski, M | 1 |
| Boulton, AA | 5 |
| Pollitt, RJ | 1 |
| Majer, JR | 1 |
| Sandler, M | 6 |
| Da Prada, M | 1 |
| Keller, HH | 1 |
| Pieri, L | 1 |
| Kettler, R | 1 |
| Haefely, WE | 1 |
| Karoum, F | 1 |
| Chuang, LW | 1 |
| Eisler, T | 1 |
| Calne, DB | 1 |
| Liebowitz, MR | 1 |
| Quitkin, FM | 1 |
| Klein, DF | 1 |
| Wyatt, RJ | 1 |
| Andrew, R | 1 |
| Watson, DG | 1 |
| Best, SA | 1 |
| Midgley, JM | 1 |
| Wenlong, H | 1 |
| Petty, RK | 1 |
| Riederer, P | 1 |
| Gargalidis-Moudanos, C | 1 |
| Pizzinat, N | 1 |
| Javoy-Agid, F | 1 |
| Remaury, A | 1 |
| Parini, A | 1 |
| Cohen, G | 3 |
| Farooqui, R | 1 |
| Kesler, N | 2 |
| Chouinard, S | 1 |
| Volz, HP | 1 |
| Gleiter, CH | 1 |
| Dalmaz, Y | 1 |
| Peyrin, L | 1 |
| Elsworth, JD | 1 |
| Glover, V | 2 |
| Reynolds, GP | 1 |
| Lees, AJ | 2 |
| Phuapradit, P | 1 |
| Shaw, KM | 1 |
| Stern, GM | 4 |
| Kumar, P | 1 |
| Knoll, J | 1 |
| Ashford, A | 1 |
| Bronaugh, RL | 1 |
| Hattox, SE | 1 |
| Hoehn, MM | 1 |
| Murphy, RC | 1 |
| Rutledge, CO | 1 |
| Siirtola, T | 1 |
| Sonninen, V | 1 |
| Rinne, UK | 1 |
| Finberg, JP | 1 |
| Ruthven, CR | 2 |
| Goodwin, BL | 2 |
| Hunter, KR | 1 |
| Godwin-Austen, RB | 1 |
| Lind, NA | 1 |
| Turner, P | 1 |
| Marjerrison, GL | 1 |
| Wu, PH | 1 |
| Boulton, A | 1 |
| Marjerrison, L | 1 |
| Majer, D | 1 |
| Marjerrison, G | 2 |
| Rajput, AH | 1 |
| Goodall, M | 1 |
| Alton, H | 1 |
| Barbeau, A | 1 |
| Rajput, A | 1 |
| Smith, I | 1 |
| Kellow, AH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identifying the Pathophysiology of Neurogenic Orthostatic Hypotension and the Effects of Melatonin on Reducing Supine Hypertension in Peripherally Intact Versus Denervated Post-ganglionic Sympathetic Nerves[NCT02963181] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-03-01 | Terminated (stopped due to PI leaving) | ||
| Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study[NCT03843944] | Phase 4 | 20 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for tyramine and Parkinson Disease
| Article | Year |
|---|---|
The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
Topics: Antiparkinson Agents; Brain; Dietary Proteins; Dose-Response Relationship, Drug; Food-Drug Interacti | 2012 |
A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Basal Ganglia; Cheese; Child; Child, Preschool; Dopam | 2004 |
[Monoamine oxidase as a target for drug action].
Topics: Alzheimer Disease; Animals; Antidepressive Agents; Antiparkinson Agents; Depression; Humans; Monoami | 2006 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bro | 1984 |
Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain; Catechol O-Methyltransferase; Catechol O-Met | 1993 |
Monoamine oxidase inhibitors. A perspective on their use in the elderly.
Topics: Aged; Alzheimer Disease; Depression; Food-Drug Interactions; Humans; Monoamine Oxidase; Monoamine Ox | 1998 |
On the dual nature of monoamine oxidase.
Topics: Animals; Antidepressive Agents; Binding Sites; Brain; Catecholamines; Clorgyline; Dose-Response Rela | 1978 |
Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
Topics: Animals; Brain; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Parkinson | 1986 |
6 trials available for tyramine and Parkinson Disease
| Article | Year |
|---|---|
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
Topics: Aged; Antihypertensive Agents; Antiparkinson Agents; Blood Pressure; Blood Pressure Monitoring, Ambu | 2008 |
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Topics: Adult; Aged; Algorithms; Contraindications; Diet; Dose-Response Relationship, Drug; Double-Blind Met | 2010 |
The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial.
Topics: Administration, Oral; Adult; Aged; Alanine; Benzylamines; Blood Pressure; Dose-Response Relationship | 2012 |
A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
Topics: Administration, Oral; Adult; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy | 2003 |
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Blood Pressure; Dose-Response Relationship, Drug; | 2006 |
Experience with tranylcypromine in early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Depression; Erectile Dysfunction; Female; Foll | 1998 |
37 other studies available for tyramine and Parkinson Disease
| Article | Year |
|---|---|
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
Topics: Binding Sites; Humans; Hydrazones; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Dyn | 2012 |
Plasma acyl-carnitines, bilirubin, tyramine and tetrahydro-21-deoxycortisol in Parkinson's disease and essential tremor. A case control biomarker study.
Topics: Aged; Bilirubin; Biomarkers; Carnitine; Case-Control Studies; Cognition; Cortodoxone; Diagnosis, Dif | 2021 |
Hordenine inhibits neuroinflammation and exerts neuroprotective effects via inhibiting NF-κB and MAPK signaling pathways in vivo and in vitro.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Lipopolysaccharides; MAP Kinase Signaling System; Micr | 2022 |
The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Propy | 2022 |
Different Circulating Trace Amine Profiles in De Novo and Treated Parkinson's Disease Patients.
Topics: Adult; Aged; Biogenic Amines; Biomarkers; Cross-Sectional Studies; Disease Progression; Early Diagno | 2019 |
Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension.
Topics: Adrenergic beta-Agonists; Aged; Autonomic Nervous System Diseases; Blood Pressure; Dopamine; Female; | 2009 |
Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension.
Topics: Aged; Blood Pressure; Bradycardia; Cholinesterase Inhibitors; Edrophonium; Epinephrine; Female; Gluc | 2008 |
Selective MAO-B inhibitors have low potential for the tyramine effect.
Topics: Blood Pressure; Heart Rate; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Tyramin | 2010 |
Attenuated pre-ejection period response to tyramine in patients with cardiac sympathetic denervation.
Topics: Aged; Autonomic Nervous System Diseases; Female; Heart; Hemodynamics; Humans; Male; Middle Aged; Par | 2008 |
Systemic postganglionic adrenergic studies do not distinguish Parkinson's disease from multiple system atrophy.
Topics: Adrenergic Agonists; Aged; Analysis of Variance; Baroreflex; Blood Pressure; Cohort Studies; Diagnos | 2009 |
Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catecholamines; Cell Respiration; Dopamine | 2004 |
Identity of a urinary "pink spot" in schizophrenia and Parkinson's disease.
Topics: Chromatography, Paper; Humans; Infrared Rays; Parkinson Disease; Phenethylamines; Schizophrenia; Spe | 1967 |
Monoamine oxidase inhibitors and their pharmacological significance.
Topics: Animals; Antidepressive Agents; Brain; Clorgyline; Humans; Monoamine Oxidase; Monoamine Oxidase Inhi | 1983 |
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Co | 1982 |
The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls.
Topics: Biogenic Monoamines; Dopamine; Gas Chromatography-Mass Spectrometry; Humans; Hydroxydopamines; Levod | 1993 |
I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Brain; Cerebral Cortex; Female; Humans; Idazoxan; Imidazoline Receptors; Ma | 1997 |
Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow.
Topics: Animals; Benzylamines; Brain; Dopamine; Electron Transport; Glutathione; Glutathione Disulfide; Huma | 1997 |
Monoamine oxidase and mitochondrial respiration.
Topics: Animals; Disulfides; Electron Transport; Electron Transport Complex I; Glutathione; Hydrogen Peroxid | 1999 |
Oxidative stress, mitochondrial respiration, and Parkinson's disease.
Topics: Animals; Brain; Dopamine; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidative S | 2000 |
Specific ion-exchange chromatography and fluorimetric assay for urinary 3-O-methyldopamine.
Topics: Adrenal Gland Neoplasms; Animals; Chromatography, Ion Exchange; Dogs; Dopamine; Humans; Hydrogen-Ion | 1976 |
Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.
Topics: Adult; Aged; Blood Platelets; Cheese; Female; Humans; Hypertension; Intestinal Mucosa; Male; Middle | 1978 |
Absence of "cheese effect" during deprenyl therapy: some recent studies.
Topics: Amphetamines; Animals; Blood Pressure; Humans; Intestines; Monoamine Oxidase; Parkinson Disease; Phe | 1978 |
Recent observations on the clinical pharmacology of (-)deprenyl.
Topics: Adult; Aged; Blood Pressure; Drug Therapy, Combination; Heart Rate; Humans; Levodopa; Middle Aged; P | 1978 |
The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of Parkinsonian patients.
Topics: Administration, Oral; Aged; Chromatography, Gas; Chromatography, High Pressure Liquid; Chromatograph | 1975 |
Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Benserazide; Biogenic Amines; Dopamine; Female; Homovanillic Acid; H | 1975 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Hu | 1987 |
Variation of levodopa metabolism with gastrointestinal absorption site.
Topics: Administration, Oral; Aged; Animals; Biotransformation; Catechols; Dihydroxyphenylalanine; Dogs; Duo | 1974 |
Mydriatic responses to sympathomimetic amines in patients treated with L-dopa.
Topics: Adrenergic alpha-Antagonists; Dihydroxyphenylalanine; Humans; Hypotension; Mydriatics; Norepinephrin | 1969 |
Effect of L-dopa therapy on urinary p-tyramine excretion and EEG changes in Parkinson's disease.
Topics: Brain; Carbon Isotopes; Dihydroxyphenylalanine; Electroencephalography; Humans; Parkinson Disease; P | 1972 |
Effect of L-DOPA on the synthesis and excretion of tyramine.
Topics: Animals; Brain Stem; Caudate Nucleus; Cerebellum; Dopamine; Humans; Hypothalamus; Levodopa; Octopami | 1974 |
Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man.
Topics: Brain Chemistry; Chromatography; Dihydroxyphenylalanine; Dopamine; Humans; Intestines; Parkinson Dis | 1971 |
[Excretion, metabolism and central distribution of non-catecholic primary amines].
Topics: Animals; Brain; Humans; Octopamine; Parkinson Disease; Phenethylamines; Phenylacetates; Rats; Schizo | 1971 |
EEG and urinary non-catecholic amine changes during L-dopa therapy of Parkinson's disease.
Topics: Brain; Carbon Isotopes; Creatinine; Dihydroxyphenylalanine; Electroencephalography; Humans; Parkinso | 1972 |
Dopamine (3-hydroxytyramine) metabolism in parkinsonism.
Topics: Adult; Aged; Alcohols; Benzoates; Carbon Isotopes; Dopamine; Epinephrine; Humans; Male; Mandelic Aci | 1969 |
Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.
Topics: Administration, Oral; Animals; Dihydroxyphenylalanine; Haloperidol; Humans; Movement Disorders; Musc | 1970 |
Dopa therapy in parkinsonism effects on the EEG and amine metabolism.
Topics: Carbon Isotopes; Dihydroxyphenylalanine; Electroencephalography; Humans; Parkinson Disease; Tyramine | 1971 |
Aromatic amines and Parkinson's disease.
Topics: Chemistry, Clinical; Chromatography, Paper; Creatinine; Dopamine; Fluorometry; Humans; Parkinson Dis | 1969 |